Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Journal of Cardiovascular Development and Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2308-3425/10/6/236 |
| _version_ | 1797594169835782144 |
|---|---|
| author | Francesco Piccirillo Paola Liporace Annunziata Nusca Vincenzo Nafisio Andrea Corlianò Francesca Magarò Raffaele Antonelli Incalzi Gian Paolo Ussia Francesco Grigioni |
| author_facet | Francesco Piccirillo Paola Liporace Annunziata Nusca Vincenzo Nafisio Andrea Corlianò Francesca Magarò Raffaele Antonelli Incalzi Gian Paolo Ussia Francesco Grigioni |
| author_sort | Francesco Piccirillo |
| collection | DOAJ |
| description | Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes. |
| first_indexed | 2024-03-11T02:19:48Z |
| format | Article |
| id | doaj.art-d372de9df7124f66ba95871c1777320b |
| institution | Directory Open Access Journal |
| issn | 2308-3425 |
| language | English |
| last_indexed | 2024-03-11T02:19:48Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Cardiovascular Development and Disease |
| spelling | doaj.art-d372de9df7124f66ba95871c1777320b2023-11-18T10:57:22ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252023-05-0110623610.3390/jcdd10060236Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive ReviewFrancesco Piccirillo0Paola Liporace1Annunziata Nusca2Vincenzo Nafisio3Andrea Corlianò4Francesca Magarò5Raffaele Antonelli Incalzi6Gian Paolo Ussia7Francesco Grigioni8Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, ItalyPatients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes.https://www.mdpi.com/2308-3425/10/6/236chronic kidney diseasecardiovascular diseasetype 2 diabetesmineralocorticoid receptormineralocorticoid receptor antagonistfinerenone |
| spellingShingle | Francesco Piccirillo Paola Liporace Annunziata Nusca Vincenzo Nafisio Andrea Corlianò Francesca Magarò Raffaele Antonelli Incalzi Gian Paolo Ussia Francesco Grigioni Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review Journal of Cardiovascular Development and Disease chronic kidney disease cardiovascular disease type 2 diabetes mineralocorticoid receptor mineralocorticoid receptor antagonist finerenone |
| title | Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review |
| title_full | Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review |
| title_fullStr | Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review |
| title_full_unstemmed | Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review |
| title_short | Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review |
| title_sort | effects of finerenone on cardiovascular and chronic kidney diseases a new weapon against cardiorenal morbidity and mortality a comprehensive review |
| topic | chronic kidney disease cardiovascular disease type 2 diabetes mineralocorticoid receptor mineralocorticoid receptor antagonist finerenone |
| url | https://www.mdpi.com/2308-3425/10/6/236 |
| work_keys_str_mv | AT francescopiccirillo effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT paolaliporace effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT annunziatanusca effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT vincenzonafisio effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT andreacorliano effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT francescamagaro effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT raffaeleantonelliincalzi effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT gianpaoloussia effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview AT francescogrigioni effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview |